Hepatitis D breakthrough: Chinese-built antibody Libevitug offering hope for cirrhosis reversal
-
-
REFERENCES
[1] Yan H., Zhong G., Xu G., et al. (2012). Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049. DOI:10.7554/eLife.00049 [2] Li D., He W., Liu X., et al. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. eLife 6:e26738. DOI:10.7554/eLife.26738 [3] Wang X., Chi X., Zhang Y., et al. (2025). Safety and Efficacy of Libevitug in Patients with Chronic Hepatitis B and D Virus Co-Infection: A Single-Center, Open-Label, Phase IIa Trial in China. Hepatology Communications (Manuscript HEP-25-1316.R2)PUBLIC SUMMARY. -
ABOUT THIS ARTICLE
Cite this article:
Editorial Team (2026). Hepatitis D breakthrough: Chinese-built antibody Libevitug offering hope for cirrhosis reversal. The Innovation Drug Discovery 1:100003. https://doi.org/10.59717/j.xinn-drugdisc.2026.100003
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Editorial Team (2026). Hepatitis D breakthrough: Chinese-built antibody Libevitug offering hope for cirrhosis reversal. The Innovation Drug Discovery 1:100003. https://doi.org/10.59717/j.xinn-drugdisc.2026.100003
Format
Content
DownLoad:
-
Figure 1.
Libevitug approved in China as first-in-class treatment for hepatitis D
